{"prompt": "['2016N277425_00', 'CONFIDENTIAL', '2018N377698_00', '201749', 'Liver Chemistry Stopping Criteria - Liver Stopping Event', 'MONITORING:', 'hypersensitivity, on the AE report form', 'For bilirubin or INR criteria:', 'Record use of concomitant medications on', 'Repeat liver chemistries (include ALT, AST,', 'the concomitant medications report form', 'alkaline phosphatase, bilirubin) and perform', 'including acetaminophen, herbal', 'liver event follow up assessments within 24', 'remedies, other over the counter', 'medications.', 'hrs', 'Record alcohol use on the liver event', 'Monitor subjects twice weekly until liver', 'chemistries resolve, stabilize or return to', 'alcohol intake case report form', 'within normal ranges.', 'A specialist or hepatology consultation is', 'For bilirubin or INR criteria:', 'recommended', 'Anti-nuclear antibody, anti-smooth muscle', 'For All other criteria:', 'antibody, Type 1 anti-liver kidney', 'microsomal antibodies, and quantitative', 'Repeat liver chemistries (include ALT, AST,', 'total immunoglobulin G (lgG or gamma', 'alkaline phosphatase, bilirubin) and perform', 'globulins).', 'liver event follow up assessments within 24-', '72 hrs', 'Serum acetaminophen adduct HPLC', 'assay (quantifies potential acetaminophen', 'Monitor subjects weekly until liver', 'contribution to liver injury in subjects with', 'chemistries resolve, stabilize or return to', 'definite or likely acetaminophen use in the', 'within normal ranges.', 'preceding week [James, 2009]). NOTE:', 'not required in China', 'Liver imaging (ultrasound, magnetic', 'resonance, or computerised tomography)', 'and /or liver biopsy to evaluate liver', 'disease; complete Liver Imaging and/or', 'Liver Biopsy CRF forms.', '1.', 'Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not', 'immediately available, discontinue study treatment for that subject if ALT 3xULN and bilirubin 2xULN.', 'Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary', 'bilirubin on dipstick, indicating direct bilirubin elevations and suggesting liver injury.', '2.', 'All events of ALT > 3xULN and bilirubin > 2xULN (>35% direct bilirubin) or ALT 3xULN and INR>1.5, if INR', \"measured which may indicate severe liver injury (possible 'Hy's Law'), must be reported as an SAE (excluding\", 'studies of hepatic impairment or cirrhosis); INR measurement is not required and the threshold value stated', 'will not apply to subjects receiving anticoagulants', '3.', 'New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper', 'quadrant pain or tenderness, or jaundice) or believed to be related to hypersensitivity (such as fever, rash or', 'eosinophilia)', '4.', 'Includes: Hepatitis A IgM antibody; Hepatitis B surface antigen and Hepatitis B Core Antibody (IgM); Hepatitis C', 'RNA; Cytomegalovirus IgM antibody; Epstein-Barr viral capsid antigen IgM antibody (or if unavailable, obtain', 'heterophile antibody or monospot testing); Hepatitis E IgM antibody', '5.', 'If hepatitis delta antibody assay cannot be performed, it can be replaced with a PCR of hepatitis D RNA virus', '(where needed) [Le Gal, 2005].', '6.', 'PK sample may not be required for subjects known to be receiving placebo or non-GSK comparator treatments.', 'Record the date/time of the PK blood sample draw and the date/time of the last dose of study treatment prior to', \"blood sample draw on the CRF. If the date or time of the last dose is unclear, provide the subject's best\", '71']['2016N277425_00', 'CONFIDENTIAL', '2018N377698_00', '-', '201749', 'approximation. If the date/time of the last dose cannot be approximated OR a PK sample cannot be collected in', 'the time period indicated above, do not obtain a PK sample. Instructions for sample handling and shipping are in', 'the SRM.', '72']\n\n###\n\n", "completion": "END"}